ATM – PROSTATE WARRIORS – The latest news about prostate cancer

Tag Archive for: ATM

Phase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors

August 29, 2025/in Clinical Trial, Metastatic, Phase 1/by Max

Phase 1: SYN608 Targets DNA Repair in HRR-Deficient Prostate and Other Solid Tumors

July 30, 2025/in Clinical Trial, Metastatic, Phase 1/by Max

ATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations)

June 13, 2025/in Not PCa related/by Max

TALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)

May 26, 2025/in Clinical Trial, Metastatic, Phase 3/by Max

AI-Designed ATR Inhibitors Advance to Preclinical Testing

March 13, 2025/in Preclinical Research/by Max

Talazoparib Plus Enzalutamide in HRR-Deficient mCRPC: Final Overall Survival Results from TALAPRO-2

February 15, 2025/in Clinical Trial, Metastatic, Phase 3/by Max

ASCO GU 2025: Impact of Homologous Recombination Repair Alterations on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (BRCA, ATM, CDK12,…)

February 14, 2025/in Observational, Retrospective studies/by Max

PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair

January 18, 2025/in Review/by Max

Phase 1 Trial of a Polynucleotide Kinase/Phosphatase (PNKP) Inhibitor

January 10, 2025/in Clinical Trial, Not PCa related/by Max

Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins

December 8, 2024/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by Max